

Unless defined herein, terms used in this announcement shall have the same meanings as those defined in the prospectus dated December 17, 2015 (the “**Prospectus**”) issued by Genscript Biotech Corporation (the “**Company**”).

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for securities. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Shares being offered.

This announcement is not an offer of securities for sale in the United States. The Company has not registered and does not intend to register any securities referred to in this announcement under the United States Securities Act of 1933, as amended (the “**U.S. Securities Act**”). Securities of the Company may not be offered or sold in the United States absent registration under the U.S. Securities Act or an applicable exemption from the registration requirements under the U.S. Securities Act. There will not be and is not currently intended to be any public offering of securities in the United States.

In connection with the Global Offering, Haitong International Securities Company Limited, as the stabilizing manager (the “**Stabilizing Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may effect transactions with a view to stabilizing or supporting the market price of the Shares at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager, its affiliates or any person acting for it, to conduct any such stabilizing action, which, if commenced, will be done at the sole and absolute discretion of the Stabilizing Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilizing activity is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules, as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Potential investors should be aware that stabilizing action cannot be taken to support the price of the Shares for longer than the stabilization period which begins on the Listing Date and is expected to expire on Thursday, January 21, 2016, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilizing action may be taken, and demand for the Shares and the price of the Shares could fall.



Genscript Biotech Corporation

金斯瑞生物科技股份有限公司*

(incorporated in the Cayman Islands with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 400,000,000 Shares (subject to adjustment and the Over-allotment Option)
Number of Hong Kong Public Offer Shares	: 40,000,000 Shares (subject to adjustment)
Number of International Offer Shares	: 360,000,000 Shares (subject to adjustment and the Over-allotment Option)
Maximum Offer Price	: HK\$1.68 per Offer Share (payable in full on application, plus a brokerage of 1.0%, an SFC transaction levy of 0.0027% and a Hong Kong Stock Exchange trading fee of 0.005% and subject to refund) and expected to be not less than HK\$1.31 per Offer Share
Nominal value	: US\$0.001 per Share
Stock code	: 1548

Sole Sponsor



Joint Global Coordinators and Joint Bookrunners



J.P.Morgan

* For identification purposes only

Application has been made by the Company to the Listing Committee for the listing of, and permission to deal in, the Shares in issue and to be issued pursuant to the Global Offering and the Capitalisation Issue (including any additional Shares which may be issued pursuant to the exercise of the Over-allotment Option and the exercise of any option which have been or may be granted under the Share Option Schemes). The Global Offering comprises (a) the Hong Kong Public Offering of 40,000,000 Shares (subject to adjustment) and (b) the International Offering of 360,000,000 Shares (subject to adjustment and the Over-allotment Option), representing 10% and 90%, respectively of the Shares to be issued pursuant to the Global Offering (without taking into account the exercise of the Over-allotment Option).

Subject to the granting of the approval for the listing of, and permission to deal in, the Shares on the Hong Kong Stock Exchange and compliance with the stock admission requirements of HKSCC, the Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the Shares on the Hong Kong Stock Exchange or such other date as may be determined by HKSCC. Settlement of transactions between participants of the Hong Kong Stock Exchange is required to take place in CCASS on the second Business Day after any trading day. All activities under CCASS are subject to the General Rules of CCASS and CCASS Operational Procedures in effect from time to time. All necessary arrangements have been made to enable the Shares to be admitted into CCASS.

In connection with the International Offering, the Company is expected to grant the Over-allotment Option to the International Underwriters, exercisable by the Joint Global Coordinators at their sole and absolute discretion on behalf of the International Underwriters for up to 30 days after the last day for the lodging of applications under the Hong Kong Public Offering. Pursuant to the Over-allotment Option, the Joint Global Coordinators will have the right to require the Company to issue and allot up to an aggregate of 60,000,000 Shares, representing in aggregate 15% of the initial number of the Offer Shares at the Offer Price to cover over-allocations in the International Offering, if any. The allocation of the Shares between the Hong Kong Public Offering and the International Offering is subject to adjustment as stated in the section headed “Structure of the Global Offering — The Hong Kong Public Offering — Reallocation” in the Prospectus.

Assuming the Global Offering becomes unconditional at or before 8:00 a.m. in Hong Kong on Wednesday, December 30, 2015, it is expected that dealings in the Shares on the Hong Kong Stock Exchange will commence at 9:00 a.m. on Wednesday, December 30, 2015. In the event that the Over-allotment Option is exercised, an announcement will be made by the Company on the websites of the Hong Kong Stock Exchange and the Company at www.hkexnews.hk and at www.genscript.com, respectively.

The Offer Price will not be more than HK\$1.68 per Offer Share and is expected to be not less than HK\$1.31 per Offer Share. Applicants for the Hong Kong Public Offer Shares are required to pay, on application, the maximum Offer Price of HK\$1.68 per Offer Share together with a brokerage of 1.0%, an SFC transaction levy of 0.0027% and a Hong Kong Stock Exchange trading fee of 0.005%, subject to refund if the Offer Price as finally determined is less than HK\$1.68 per Offer Share.

Applications for the Hong Kong Public Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus, the Application Forms and the designated website (www.eipo.com.hk) for the White Form eIPO.

Applicants who would like to have the Hong Kong Public Offer Shares to be allotted and issued in their own names should:

- (i) complete and sign the **WHITE** Application Forms; or
- (ii) submit applications online through the designated website of the **White Form eIPO** Service Provider at www.eipo.com.hk under the **White Form eIPO** service.

Applicants who would like to have the Hong Kong Public Offer Shares to be allotted and issued in the name of HKSCC Nominees Limited and deposited directly into CCASS for credit to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participants maintained in CCASS should either:

- (i) complete and sign the **YELLOW** Application Forms; or
- (ii) give **electronic application instructions** to HKSCC via CCASS.

Copies of the Prospectus, together with the **WHITE** Application Forms, may be obtained during normal business hours from 9:00 a.m. on Thursday, December 17, 2015 until 12:00 noon on Tuesday, December 22, 2015 from:

- (1) the following office of the Hong Kong Underwriters:

**Haitong International
Securities Company Limited**

22/F Li Po Chun Chambers
189 Des Voeux Road Central
Hong Kong

J.P. Morgan Securities (Asia Pacific) Limited

28th Floor, Chater House
8 Connaught Road Central
Hong Kong

(2) any of the following branches of the receiving banks for the Hong Kong Public Offering:

(1) **Bank of Communications Co., Ltd. Hong Kong Branch**

District	Branch Name	Address
Hong Kong Island	Hong Kong Branch	20 Pedder Street, Central
	Taikoo Shing Sub-Branch	Shop 38, G/F., CityPlaza 2, 18 Taikoo Shing Road
Kowloon	Jordan Road Sub-Branch	1/F., Booman Building, 37U Jordan Road
	Wong Tai Sin Sub-Branch	Shop N118, 1/F, Temple Mall North, 136 Lung Cheung Road, Wong Tai Sin
New Territories	Tiu Keng Leng Sub-Branch	Shops Nos. L2-064 and L2-065, Level 2, Metro Town, Tiu Keng Leng

(2) **Standard Chartered Bank (Hong Kong) Limited**

District	Branch Name	Address
Hong Kong Island	88 Des Voeux Road Branch	88 Des Voeux Road Central, Central, Hong Kong
	Causeway Bay Branch	G/F to 2/F, Yee Wah Mansion, 38–40A Yee Wo Street, Causeway Bay, Hong Kong
	Quarry Bay Branch	G/F, Westlands Gardens, 1027 King's Road, Quarry Bay, Hong Kong

District	Branch Name	Address
Kowloon	Telford Gardens Branch	Shop P9–12, Telford Centre, Telford Gardens, Tai Yip Street, Kwun Tong, Hong Kong
	Mei Foo Stage I Branch	G/F, 1C Broadway, Mei Foo Sun Chuen Stage I, Lai Chi Kok, Hong Kong
New Territories	Tsuen Wan Branch	Shop C, G/F & 1/F, Jade Plaza, 298 Sha Tsui Road, Tsuen Wan, Hong Kong
	Metroplaza Branch	Shop No. 175–176, Level 1, Metroplaza, 223 Hing Fong Road, Kwai Chung, Hong Kong

Copies of the Prospectus, together with the **YELLOW** Application Form, may be obtained during normal business hours from 9:00 a.m. on Thursday, December 17, 2015 until 12:00 noon on Tuesday, December 22, 2015 at the **Depository Counter of HKSCC** at 1/F, One & Two Exchange Square, 8 Connaught Place, Central, Hong Kong or your stockbroker.

Your completed **WHITE** or **YELLOW** Application Form, together with a cheque or a banker’s cashier order marked payable to “Bank of Communications (Nominee) Co. Ltd. – Genscript Biotech Public Offer” attached and securely stapled, should be deposited in the special collection boxes provided at any of the branches of the receiving banks listed above, at the following dates and times:

Thursday, December 17, 2015 – 9:00 a.m. to 5:00 p.m.
Friday, December 18, 2015 – 9:00 a.m. to 5:00 p.m.
Saturday, December 19, 2015 – 9:00 a.m. to 1:00 p.m.
Monday, December 21, 2015 – 9:00 a.m. to 5:00 p.m.
Tuesday, December 22, 2015 – 9:00 a.m. to 12:00 noon

Applicants applying by **White Form eIPO** service may submit applications through the designated website at www.eipo.com.hk from 9:00 a.m. on Thursday, December 17, 2015 until 11:30 a.m. on Tuesday, December 22, 2015 (24 hours daily, except on the last application day) or such later time as described in the section headed “*How to Apply for Hong Kong Public Offer Shares — Effect of Bad Weather on the Opening of the Application Lists*” in the Prospectus.

CCASS Participants can input **electronic application instructions** from 9:00 a.m. on Thursday, December 17, 2015 until 12:00 noon on Tuesday, December 22, 2015 or such later time as described in the section headed “*How to Apply for Hong Kong Public Offer Shares — Effect of Bad Weather on the Opening of the Application Lists*” in the Prospectus. Please refer to the sections headed “*Structure of the Global Offering*” and “*How to Apply for Hong Kong Public Offer Shares*” in the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

The Company expects to publish an announcement on the final Offer Price, the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Public Offer Shares on Tuesday, December 29, 2015 in the South China Morning Post (in English) and Hong Kong Economic Times (in Chinese), and on the websites of the Hong Kong Stock Exchange and the Company at www.hkexnews.hk and at www.genscript.com, respectively. The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration numbers of successful applicants under the Hong Kong Public Offering will be made available through a variety of channels from Tuesday, December 29, 2015 as described in the section headed “*How to Apply for Hong Kong Public Offer Shares — Publication of Results*” in the Prospectus.

No temporary documents of title will be issued in respect of the Shares and no receipt will be issued for sums paid on application. Share certificates will only become valid certificates of title at 8:00 a.m. on Wednesday, December 30, 2015 provided that the Global Offering has become unconditional in all respects and the right of termination described in the section headed “*Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination of the Hong Kong Underwriting Agreement*” has not been exercised.

Dealings in the Shares on the Hong Kong Stock Exchange are expected to commence at 9:00 a.m. on Wednesday, December 30, 2015. The Shares will be traded in board lots of 2,000 Shares each and the stock code of the Company is 1548.

By Order of the Board
Genscript Biotech Corporation
Zhang Fangliang
Chairman

Hong Kong
December 17, 2015

As at the date of this announcement, the executive Directors are Mr. Zhang Fangliang, Ms. Wang Ye and Mr. Meng Jiange, the non-executive Directors are Mr. Wang Luquan, Mr. Huang Zuie-Chin and Mr. Pan Yuexin and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian and Ms. Zhang Min.

Please also refer to the published version of this announcement in English in the South China Morning Post and in Chinese in Hong Kong Economic Times.